Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. Interius is developing new ways to engineer cells inside the human body, right where they live. Our lead programs are initially focused on treating hematologic malignancies by leveraging the Interius platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.
We are also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.
Total Funding: $81.5 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Interius BioTherapeutics
Director, Analytical Method Development and Testing
Philadelphia, Pennsylvania
Research Assistant or Research Associate
Philadelphia, Pennsylvania
Scientist/Sr Scientist/Principal Scientist
Philadelphia, Pennsylvania
Senior Scientist, Viral Vector Process Development – Upstream
Philadelphia, Pennsylvania
Senior Scientist, Viral Vector Process Development – Downstream
Philadelphia, Pennsylvania
